Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
Kronos Bio, Inc. (KRON)
Company Research
Source: GlobeNewswire
– Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today highlighted preclinical data from its p300 KAT inhibitor program for autoimmune indications at the American College of Rheumatology's annual meeting, ACR Convergence 2024. The oral presentation will take place on Monday, November 18, 2024, from 4:15 p.m. to 4:30 p.m. EST. Kronos Bio has been exploring the utility of KB-7898, a p300 KAT inhibitor, for autoimmune indications given the role of interferon regulatory factor 4 (IRF4) and p300 in B cells, T cells and other immune cells. The data demonstrates the ability of p300
Show less
Read more
Impact Snapshot
Event Time:
KRON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRON alerts
High impacting Kronos Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KRON
News
- Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 [Yahoo! Finance]Yahoo! Finance
- Kronos Bio, Inc. (NASDAQ: KRON) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating.MarketBeat
- Kronos Bio, Inc. (NASDAQ: KRON) was downgraded by analysts at Piper Sandler from an "overweight" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $6.00.MarketBeat
- Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic AlternativesGlobeNewswire
KRON
Earnings
- 11/13/24 - Beat
KRON
Analyst Actions
- 8/19/24 - HC Wainwright
KRON
Sec Filings
- 11/14/24 - Form SC
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- KRON's page on the SEC website